Research programme: inflammation and rheumatoid arthritis therapeutics - Piramal Healthcare

Drug Profile

Research programme: inflammation and rheumatoid arthritis therapeutics - Piramal Healthcare

Alternative Names: IL6 - Piramal; P 979

Latest Information Update: 31 Mar 2011

Price : $50

At a glance

  • Originator Nicholas Piramal India Limited
  • Developer Piramal Enterprises
  • Class Small molecules
  • Mechanism of Action Interleukin 6 inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Preclinical Inflammation; Rheumatoid arthritis

Most Recent Events

  • 31 Dec 2008 Preclinical trials in Inflammation in India (unspecified route)
  • 15 Dec 2005 Data presented at the 69th Annual Scientific Meeting of the American College of Rheumatology and the 40th Annual Meeting of the Association of Rheumatology Health Professionals (ACR/ARHP-2005) have been added to the adverse events, pharmacokinetics and Rheumatic disease pharmacodynamics section
  • 31 Mar 2004 Preclinical trials in Rheumatoid arthritis in India (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top